Joseph Fortunak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joseph Fortunak has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Charles Verharen
Department of Philosophy, Howard University, Washington, USA
2 shared publications - F. Bugarin
Department of African Studies, Howard University, Washington, DC 20059, USA
2 shared publications - G. Kadoda
Independent Researcher, Khartoum, 13314 Sudan
2 shared publications - George Middendorf
Howard University Department of Biology Washington, DC 20059
2 shared publications - John Tharakan
Department of Chemical Engineering, Howard University, Washington, DC 20059, USA
2 shared publications - Andrew Hill
Department of Pharmacology and Therapeutics, University of Liverpool , Liverpool
1 shared publication
Latest Publications
- 4 July 2017
- Published by Taylor & Francis in African Journal of Science, Technology, Innovation and Development
- Vol. 9 (4) , 467-477
Appropriate technology and ethical obligations of the university: W.E.B. Du Bois on the Africana university mission
Working on the Encyclopedia Africana under the sponsorship of Kwame Nkrumah in Ghana, W.E.B. Du Bois reversed his conviction that only the ‘talented tenth’ could profit from a university education. He proposed that virtually all humans have a right to a university education. He further insisted that Africana (African and African in the Diaspora) universities are ethically obligated and uniquely positioned to spearhead a movement to train students to become professionals who solve problems community members are unable to solve for themselves. Africana universities can, with the aid of appropriate technology and service learning, take the steps necessary to achieve Du Bois’s vision. In this paper, we present a practical account of how universities may work with local communities to determine the questions to research and then deploy appropriate technologies through community-based but student-driven service learning projects. Our hypothesis is that students can become community leaders of tomorrow by partnering with community members to solve theoretical issues and practical problems of their communities. As university graduates inspired by Du Bois’s vision for Africana universities, their mission will be to establish alumni communities of learning that transfer problem-solving skills to community members who do not yet have access to university education.
- 4 July 2017
- Published by Taylor & Francis in African Journal of Science, Technology, Innovation and Development
- Vol. 9 (4) , 467-477
Appropriate technology and ethical obligations of the university: W.E.B. Du Bois on the Africana university mission
Working on the Encyclopedia Africana under the sponsorship of Kwame Nkrumah in Ghana, W.E.B. Du Bois reversed his conviction that only the ‘talented tenth’ could profit from a university education. He proposed that virtually all humans have a right to a university education. He further insisted that Africana (African and African in the Diaspora) universities are ethically obligated and uniquely positioned to spearhead a movement to train students to become professionals who solve problems community members are unable to solve for themselves. Africana universities can, with the aid of appropriate technology and service learning, take the steps necessary to achieve Du Bois’s vision. In this paper, we present a practical account of how universities may work with local communities to determine the questions to research and then deploy appropriate technologies through community-based but student-driven service learning projects. Our hypothesis is that students can become community leaders of tomorrow by partnering with community members to solve theoretical issues and practical problems of their communities. As university graduates inspired by Du Bois’s vision for Africana universities, their mission will be to establish alumni communities of learning that transfer problem-solving skills to community members who do not yet have access to university education.
- Open Access
- 10 January 2017
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (4) , 1243-1252
Estimated generic prices for novel treatments for drug-resistant tuberculosis
Background: The estimated worldwide annual incidence of MDR-TB is 480 000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or repurposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of dollars per course. Objectives: To estimate generic prices for novel TB drugs that would be achievable given large-scale competitive manufacture. Methods: Prices for linezolid, moxifloxacin and clofazimine were estimated based on per-kilogram prices of the active pharmaceutical ingredient (API). Other costs were added, including formulation, packaging and a profit margin. The projected costs for sutezolid were estimated to be equivalent to those for linezolid, based on chemical similarity. Generic prices for bedaquiline, delamanid and pretomanid were estimated by assessing routes of synthesis, costs/kg of chemical reagents, routes of synthesis and per-step yields. Costing algorithms reflected variable regulatory requirements and efficiency of scale based on demand, and were validated by testing predictive ability against widely available TB medicines. Results: Estimated generic prices were US$8–$17/month for bedaquiline, $5–$16/month for delamanid, $11–$34/month for pretomanid, $4–$9/month for linezolid, $4–$9/month for sutezolid, $4–$11/month for clofazimine and $4–$8/month for moxifloxacin. The estimated generic prices were 87%–94% lower than the current lowest available prices for bedaquiline, 95%–98% for delamanid and 94%–97% for linezolid. Estimated generic prices were $168–$395 per course for the STREAM trial modified Bangladesh regimens (current costs $734–$1799), $53–$276 for pretomanid-based three-drug regimens and $238–$507 for a delamanid-based four-drug regimen. Conclusions: Competitive large-scale generic manufacture could allow supplies of treatment for 5–10 times more MDR-TB cases within current procurement budgets.
- 10 January 2017
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (4) , 1243-1252
Open AccessEstimated generic prices for novel treatments for drug-resistant tuberculosis
Background: The estimated worldwide annual incidence of MDR-TB is 480 000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or repurposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of dollars per course. Objectives: To estimate generic prices for novel TB drugs that would be achievable given large-scale competitive manufacture. Methods: Prices for linezolid, moxifloxacin and clofazimine were estimated based on per-kilogram prices of the active pharmaceutical ingredient (API). Other costs were added, including formulation, packaging and a profit margin. The projected costs for sutezolid were estimated to be equivalent to those for linezolid, based on chemical similarity. Generic prices for bedaquiline, delamanid and pretomanid were estimated by assessing routes of synthesis, costs/kg of chemical reagents, routes of synthesis and per-step yields. Costing algorithms reflected variable regulatory requirements and efficiency of scale based on demand, and were validated by testing predictive ability against widely available TB medicines. Results: Estimated generic prices were US$8–$17/month for bedaquiline, $5–$16/month for delamanid, $11–$34/month for pretomanid, $4–$9/month for linezolid, $4–$9/month for sutezolid, $4–$11/month for clofazimine and $4–$8/month for moxifloxacin. The estimated generic prices were 87%–94% lower than the current lowest available prices for bedaquiline, 95%–98% for delamanid and 94%–97% for linezolid. Estimated generic prices were $168–$395 per course for the STREAM trial modified Bangladesh regimens (current costs $734–$1799), $53–$276 for pretomanid-based three-drug regimens and $238–$507 for a delamanid-based four-drug regimen. Conclusions: Competitive large-scale generic manufacture could allow supplies of treatment for 5–10 times more MDR-TB cases within current procurement budgets.
- Open Access
- 2 January 2014
- Published by Taylor & Francis in African Journal of Science, Technology, Innovation and Development
- Vol. 6 (1) , 3-12
African philosophy: a key to African innovation and development
- 2 January 2014
- Published by Taylor & Francis in African Journal of Science, Technology, Innovation and Development
- Vol. 6 (1) , 3-12
Open AccessAfrican philosophy: a key to African innovation and development
- 29 August 2000
- Published by Wiley in ChemInform
- Vol. 31 (35)
ChemInform Abstract: A New and Practical Synthesis of Vinyl Dichlorides via a Non-Wittig-Type Approach.
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
- 29 August 2000
- Published by Wiley in ChemInform
- Vol. 31 (35)
ChemInform Abstract: A New and Practical Synthesis of Vinyl Dichlorides via a Non-Wittig-Type Approach.
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.